يعرض 1 - 20 نتائج من 34 نتيجة بحث عن '"Muscle-invasive bladder carcinoma"', وقت الاستعلام: 0.63s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal
  3. 3
    Academic Journal
  4. 4
    Academic Journal
  5. 5
    Academic Journal
  6. 6
    Academic Journal
  7. 7
    Academic Journal
  8. 8
    Academic Journal

    وصف الملف: application/pdf

    Relation: European Urology Focus; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; Liem, E., Freund, J., Savci-Heijink, C., Delarosette, J., Kamphuis, G., Baard, J. . De Bruin, D. (2020). Validation of confocal laser endomicroscopy features of bladder cancer: The next step towards real-time histologic grading. Journal of European Urology Focus, 6(1), 81-87. https://dx.doi.org/10.1016/j.euf.2018.07.012; https://hdl.handle.net/20.500.12511/1377; https://dx.doi.org/10.1016/j.euf.2018.07.012; 81; 87; Q1

  9. 9
    Academic Journal
  10. 10
  11. 11
    Academic Journal

    المصدر: Beji , S , Wrist Lam , G , Østergren , P B , Toxvaerd , A , Sønksen , J & Fode , M 2021 , ' Diagnostic value of probe-based confocal laser endomicroscopy versus conventional endoscopic biopsies of non-muscle invasive bladder tumors : a pilot study ' , Scandinavian Journal of Urology , vol. 55 , no. 1 , pp. 36-40 . https://doi.org/10.1080/21681805.2020.1841285

  12. 12
    Academic Journal

    المصدر: Cancer Urology; Том 6, № 4 (2010); 36-41 ; Онкоурология; Том 6, № 4 (2010); 36-41 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2010-6-4

    وصف الملف: application/pdf

    Relation: https://oncourology.abvpress.ru/oncur/article/view/331/349; Чиссов В.И., Старинский В.В. Состояние онкологической помощи населению России в 2009 г. М., 2010.; Русаков И.Г., Соколов В.В., Булгакова Н.Н. и др. Фотодинамическая диагностика и флуоресцентная спектроскопия при поверхностном раке мочевого пузыря. Онкоурология 2009;(4):41–6.; Карякин О.Б. Комбинированное лечение местно-распространенного и распространенного рака мочевого пузыря. Автореф. дис. … д-ра мед. наук. Обнинск, 1996.; Фигурин К.М. Химиотерапия и иммунотерапия рака мочевого пузыря. Дис. … д-ра мед. наук. М., 1993.; Sylvester R.J., van der Meijden A., Oosterlinck W. et al. Predicting recurrence and progression in individual patients with stage Ta–T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49(3):466–77.; Шацева Т.А., Мухина М.С. Антиген Ki-67 в оценке опухолевой пролиферации. Его структура и функции. Вопр Онкол 2004;50(2):157–64.; Комарова Е.А., Гудков А.В. Супрессия р53: новый подход к преодолению побочных эффектов противоопухолевой терапии. Биохимия 2000;65(1):48–56.; Петровичев Н.Н. Основные направления в патологоанатомической диагностике опухолей человека. Вестн РАМН 2001;(9):33–8.; Habuchi T., Marberger M., Droller M.J. et al. Prognostic markers for bladder cancer: international consensus panel on bladder tumor markers. Urology 2005; 66):64–74.; Shim J.W., Cho K.S., Choi Y.D. et al. Diagnostic algorithm for papillary urothelial tumors in the urinary bladder. Virchows Arch 2008;452(4):353–62.; Burger M., Madelon N.M. van der Aa M.N.M. et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol 2008;(54):835–44.; Quintero A., Alvares-Kindelan J., Luque R.J. et al. Ki-67 MIB1 labelling inde and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 2006;(59):83–8.; Comperat E., Camparo P., Haus R. et al. Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases. Virchows Arch 2006;448(3):319–24.; Yin H., Leong A.S.Y. Histologic grading of noninvasive papillary urothelial tumors. Am J Clin Pathol 2004;121(5):679–87.; Harnden P., Allam A., Joyce A.D. et al. Cytokeratin 20 expression by non-invasive transitional cell carcinomas: potential for distinguishing recurrent from non-recurrent disease. Histopathology 1995;27(2):169–74.; Yildiz I.Z., Recavarren R., Armah H.B. et al. Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies. Diagn Pathol 2009;4:35.; Barbisan F., Santinelli A., Mazzucchelli R. et al. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. Cancer 2008;112(3):636–44.; Hauser-Kronberger C., Peham K., Grall J. et al. Novel approach of human epidermal growth factor receptor 2 detection in noninvasive and invasive transitional cell carcinoma of the bladder. J Urol 2006;175(3 Pt 1):875–80.; Ecke T.H., Schlechte H.H., Schulze G. et al. Four tumour markers for urinary bladder cancer – tissue polypeptide antigen (TPA), Her-2/neu (Erb-B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation. Anticancer Res 2005;25(1):635–41.; Kruger S., Lange I., Kausch I. et al. Protein expression and gene copy number analysis of topoisomerase 2-alpha, Her-2 and p53 in minimally invasive urothelial carcinoma of the urinary bladder – a multitissue array study with prognostic implications. Anticancer Res 2005;25(1):263–71.; Raica M., Zylis D., Cîmpean A.M. Cytokeratin 20, 34-beta-E12 and verexpression of Her-2/neu in urine cytology as predictors of recurrences in superficial urothelial carcinoma. Rom J Morphol Embryol 2005;46(1):11–5.; Dekairelle A.F., Tombal B., Cosyns J.P. et al. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder. Clin Cancer Res 2005;11(13):4724–32; https://oncourology.abvpress.ru/oncur/article/view/331

  13. 13
    Academic Journal
  14. 14

    المساهمون: Urology, Graduate School, APH - Personalized Medicine, APH - Quality of Care, CCA - Imaging and biomarkers, Pathology, Biomedical Engineering and Physics, ACS - Atherosclerosis & ischemic syndromes

    المصدر: European urology focus, 6(1), 81-87. Elsevier BV

    وصف الملف: application/pdf

  15. 15
  16. 16
    Academic Journal
  17. 17

    المساهمون: APH - Personalized Medicine, APH - Quality of Care, CCA - Imaging and biomarkers, Graduate School, Urology, Other departments, Biomedical Engineering and Physics, CCA -Cancer Center Amsterdam, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, ACS - Atherosclerosis & ischemic syndromes

    المصدر: Medical Oncology (Northwood, London, England)
    Medical oncology (Northwood, London, England), 34(10). Humana Press

  18. 18
  19. 19
    Academic Journal
  20. 20